Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, acquired ATXCo including its core asset, PAT-409, a Phase I ready autotaxin inhibitor for patients with fibrotic diseases, from Bay City Capital and Celgene Corporation. Financial terms were not disclosed. “As ATXCo evaluated opportunities for PAT-409, it became clear that Blade’s commitment to patients with fibrosis and best-in-class team provide an excellent vehicle for its future development,” Robert Williamson, ATXCo’s President and Chief Executive Officer.